PBYI Puma Biotechnology Inc

40.14
-2.23  -5%
Previous Close 42.37
Open 43.26
Price To Book 45.1
Market Cap 1545308957
Shares 38,497,981
Volume 970,638
Short Ratio
Av. Daily Volume 1,184,877

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released at ASCO June 3, 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 additional data released March 18, 2019 - PFS 7 months, high rates of diarrhea.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data due 1H 2019.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data released December 17, 2018. PFS endpoint met but OS co-primary missed. Data to be presented 1H 2019.
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
Neratinib (NERLYNX)
Extended adjuvant HER2-positive early stage breast cancer
Phase 1/2 interim data presented at ASCO June 2018. 9 PRs, 3CRs out of 20 patients.
Neratinib plus Kadcyla (T-DM1)
HER2-positive metastatic breast cancer

Latest News

  1. Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
  2. See what the IHS Markit Score report has to say about Puma Biotechnology Inc.
  3. Why Edwards Lifesciences, Village Farms International, and Puma Biotechnology Jumped Today
  4. Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting
  5. Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
  6. Edited Transcript of PBYI earnings conference call or presentation 28-Feb-19 9:30pm GMT
  7. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  8. Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
  9. Will Puma Biotechnology Continue to Surge Higher?
  10. Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
  11. Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
  12. 3 Takeaways from Puma Biotechnology's 2018 Earnings
  13. Recent Analysis Shows Altria Group, Puma Biotechnology, Tanger Factory Outlet Centers, PTC, Aptiv, and Olin Market Influences — Renewed Outlook, Key Drivers of Growth
  14. Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results
  15. Cantor Fitzgerald Bumps Puma Biotechnology Price Target On Strong Nerlynx Sales
  16. Here's Why Puma Biotechnology Is Soaring Today
  17. Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up
  18. The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis